|
1
|
Somsen GA, Verberne HJ, Fleury E and
Righetti A: Normal values and within-subject variability of cardiac
I-123 MIBG scintigraphy in healthy individuals: Implications for
clinical studies. J Nucl Cardiol. 11:126–133. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Braak H, Ghebremedhin E, Rüb U, Bratzke H
and Del Tredici K: Stages in the development of Parkinson’s
disease-related pathology. Cell Tissue Res. 318:121–134. 2004.
|
|
3
|
Kline RC, Swanson DP, Wieland DM, et al:
Myocardial imaging in man with I-123 meta-iodobenzylguanidine. J
Nucl Med. 22:129–132. 1981.PubMed/NCBI
|
|
4
|
Spiegel J, Möllers MO, Jost WH, et al:
FP-CIT and MIBG scintigraphy in early Parkinson’s disease. Mov
Disord. 20:552–561. 2005.
|
|
5
|
Ahlskog JE: Diagnosis and differential
diagnosis of Parkinson’s disease and parkinsonism. Parkinsonism
Relat Disord. 7:63–70. 2000.
|
|
6
|
Quinn N: Parkinsonism-recognition and
differential diagnosis. Br Med J. 310:447–452. 1995. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Suzuki M, Urashima M, Oka H, Hashimoto M
and Taira K: Cardiac sympathetic denervation in
bradykinesia-dominant Parkinson’s disease. Neuroreport.
18:1867–1870. 2007.PubMed/NCBI
|
|
8
|
Spiegel J, Hellwig D, Farmakis G, et al:
Myocardial sympathetic degeneration correlates with clinical
phenotype of Parkinson’s disease. Mov Disord. 22:1004–1008.
2007.PubMed/NCBI
|
|
9
|
Hughes A, Daniel SE, Kilford L and Lees
AJ: Accuracy of clinical diagnosis of idiopatic Parkinson’s
disease: a clinico-pathological study of 100 cases. J Neurol
Neurosurg Psychiatry. 55:181–184. 1992.
|
|
10
|
Fahn S and Elton RL; members of the UPDRS
Development Committee. Unified Parkinson’s disease rating scale.
Macmillan Healthcare Information; Florhan Park HJ: 1987
|
|
11
|
Spiegel J, Hellwing D, Samnick S, et al:
Striatal FP-CIT uptake differs in the subtypes of early Parkinson’s
disease. J Neural Transm. 114:331–335. 2007.PubMed/NCBI
|
|
12
|
Schillaci O, Chiaravalloti A, Pierantozzi
M, et al: Different patterns of nigrostriatal degeneration in
tremor type versus the akinetic-rigid and mixed types of
Parkinson’s disease at the early stages: molecular imaging with
123I-FP-CIT SPECT. Int J Mol Med. 28:881–886. 2011.PubMed/NCBI
|
|
13
|
Lewis SJG, Foltynie T, Blackwell AD,
Robbins TW, Owen AM and Barker RA: Heterogeneity of Parkinson’s
disease in the early clinical stages using a data driven approach.
J Neurol Neurosurg Psychiatry. 76:343–348. 1995.
|
|
14
|
Kang GA, Bronstein JM, Masterman DL, et
al: Clinical characteristics in early Parkinson’s disease in a
central California population-based study. Mov Disord.
20:1133–1142. 1995.
|
|
15
|
Solanki KK, Bomanji J, Moyes J, Mather SJ,
Trainer PJ and Britton KE: A pharmacological guide to medicines
which interfere with the biodistribution of radiolabelled
meta-iodobenzylguanidine (MIBG). Nucl Med Commun. 14:513–521. 1992.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Courbon F, Brefel-Courbon C, Thalamas C,
et al: Cardiac MIBG scintigraphy is a sensitive tool for detecting
cardiac sympathetic denervation in Parkinson’s disease. Mov Disord.
18:890–897. 2003.
|
|
17
|
Hamada K, Hirayama M, Watanabe H, et al:
Onset age and severity of motor impairment are associated with
reduction of myocardial 123I-MIBG uptake in Parkinson’s disease. J
Neurol Neurosurg Psychiatry. 74:423–426. 2003.PubMed/NCBI
|
|
18
|
Kashihara K, Ohno M, Kawada S and Okumura
Y: Reduced cardiac uptake and enhanced washout of 123I-MIBG in pure
autonomic failure occurs conjointly with Parkinson’s disease and
dementia with lewy bodies. J Nucl Med. 47:1099–1101.
2006.PubMed/NCBI
|
|
19
|
Matsui H, Nishinaka K, Oda M, Komatsu K,
Kubori T and Udaka F: Does cardiac metaiodobenzylguanidine (MIBG)
uptake in Parkinson’s disease correlate with major autonomic
symptoms? Parkinsonism Relat Disord. 12:284–288. 2006.
|
|
20
|
Saiki S, Hirose G, Sakai K, et al: Cardiac
123I-MIBG scintigraphy can assess the disease severity and
phenotype of PD. J Neurol Sci. 220:105–111. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Hakusui S, Yasuda T, Yanagi T, et al: A
radiological analysis of heart sympathetic functions with
meta-[123I]iodobenzylguanidine in neurological patients with
autonomic failure. J Auton Nerv Syst. 49:81–84. 1994.PubMed/NCBI
|
|
22
|
Pace L, Betocchi S, Losi MA, et al:
Sympathetic nervous function in patients with hypertrophic
cardiomyopathy assessed by [123I]-MIBG: relationship with left
ventricular perfusion and function. Q J Nucl Med Mol Imaging.
48:20–25. 2004.
|
|
23
|
Sawada H, Hoeda T, Yamamoto K, et al:
Diagnostc accuracy of cardiac metaiodobenzylguanidine scintigraphy
in Parkinson disease. Eur J Neurol. 16:174–182. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Blin J, Dubois B, Bonnet AM, Vidailhet M,
Brandabur M and Agid Y: Does ageing aggravate parkinsonian
disability? J Neurol Neurosurg Psychiatry. 54:780–782. 1991.
View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Merlet P, Benvenuti C, Moyse D, et al:
Prognostic value of MIBG imaging in idiopathic dilated
cardiomyopathy. J Nucl Med. 40:917–923. 1999.PubMed/NCBI
|
|
26
|
Morozumi T, Kusuoka H, Fukuchi K, et al:
Myocardial iodine- 123-metaiodobenzylguanidine images and autonomic
nerve activity in normal subjects. J Nucl Med. 38:49–52.
1997.PubMed/NCBI
|
|
27
|
Kobayashi S, Tateno M, Morii H, Utsumi K
and Saito T: Decreased cardiac MIBG uptake, its correlation with
clinical symptoms in dementia with Lewy bodies. Psychiatry Res.
174:76–80. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Yoshita M, Taki J, Yokoyama K, et al:
Value of 123I-MIBG radioactivity in the differential diagnosis of
DLB from AD. Neurology. 66:1850–1854. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Carr J: Tremor in Parkinson’s disease.
Parkinsonism Relat Disord. 8:223–234. 2002.
|
|
30
|
Rivlin-Etzion M, Marmor O, Heimer G, Raz
A, Nini A and Bergman H: Basal ganglia oscillations and
pathophysiology of movement disorders. Curr Opin Neurobiol.
16:629–637. 2006. View Article : Google Scholar : PubMed/NCBI
|
